<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03160651</url>
  </required_header>
  <id_info>
    <org_study_id>CORTISAVE study</org_study_id>
    <nct_id>NCT03160651</nct_id>
  </id_info>
  <brief_title>Corticosteroids in Alcoholic Hepatitis</brief_title>
  <official_title>Corticosteroids in Severe Alcoholic Hepatitis Patients With Early Spontaneous Improvement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 50% of patients admitted for severe AH will have spontaneous improvement of
      liver function before initiation of therapy (ie decrease in mDF between hospital admission
      and initiation of steroids). These patients have a better prognosis than patients without
      spontaneous improvement of liver function. It has never been demonstrated that
      corticosteroids improve survival in severe AH patients with spontaneous improvement of liver
      function. Our hypothesis is that severe AH patients with spontaneous improvement of liver
      function represent a group who could most benefit from steroids
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2017</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>double-blind randomized trial Investigator, patients, and care providers will be masking Only statisticians and pharmacist will not be masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality at 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>To determine whether Methylprednisolone compared to placebo improve the 90 day mortality from patients with severe AH and spontaneous improvement of liver function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality at 28 days</measure>
    <time_frame>28 days</time_frame>
    <description>To determine the 28 day mortality from patients with severe AH and spontaneous liver function improvement treated with Methylprednisolone or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infections during the study period (90 days)</measure>
    <time_frame>90 days</time_frame>
    <description>To determine the incidence of infections during the 90 day study period in corticosteroid-treated compared to placebo-treated patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>methylprednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 28 days of methylprednisolone 32 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive 28 days of matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone or placebo</intervention_name>
    <description>Patients will receive 28 days of methylprednisolone 32 mg/day</description>
    <arm_group_label>methylprednisolone</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical syndrome of alcoholic hepatitis:

             recent jaudice or in recent aggravation (&lt; 3 months) serum bilirubin &gt; 5 mg/dL history
             of excess alcohol abuse (&gt; 40g/day)

          2. Alcoholic hepatitis proven by a liver biopsy (histological criteria of alcoholic
             hepatitis defined according to EASL clinical practice guidelines : steatosis,
             hepatocyte ballooning, and an inflammatory infiltrate with PMNs)

          3. Spontaneous liver function improvement, defined by a decrease in mDF and serum
             bilirubin level &gt; 10% between admission and day 7 after admission

          4. less than 2 weeks since admission to hospital

          5. Maddrey discriminant function* greater than or equal to 32

          6. Subjects must voluntarily sign and date an informed consent form, approved by an
             Institutional Review Board (IRB)/Independent Ethics Committee (IEC) prior to the
             initiation of any screening or study-specific procedures.

          7. Subjects must be able to understand and adhere to the study visit schedule and all
             other protocol requirements.

        Patients with significant hepatic encephalopathy are not excluded from participation to the
        trial. In this case, the patient should be accompanied by a legal representative that will
        decide participation in the clinical study and sign ICF.

        Exclusion Criteria:

          1. Other causes of liver disease including viral hepatitis (positive HBs antigen, HCV RNA
             positive), auto-immune hepatitis, biliary obstruction

          2. Other disease compromising 90-day survival

          3. Positive HIV serology

          4. Uncontrolled infection All patients will be screened for infection. This will involve
             chest radiography, urinalysis, PMNs count in ascites (if ascites present). All other
             sign or clinical suspicion of infection with or without antibiotherapy will be
             recorded as an infection.

             Positive culture and initiation of antibiotics with clinical or radiological signs of
             infection, as well as clinical suspicion, will be recorded as infection.

             Patients with evidence of sepsis will be treated for a minimum of 2 days with
             appropriate antibiotics. Once the local principal investigator considers that the
             sepsis is under control, the patient may be rescreened and randomised.

          5. Uncontrolled gastrointestinal bleeding Bleeding must be judged as controlled for at
             least 5 days

          6. Patient with serum creatinine &gt; 2.5 mg/dL, under renal replacement therapy or under
             terlipressine (or other vasoactive drugs)

          7. Pentoxyphilline therapy

          8. Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Moreno, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasme University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christophe Moreno, MD, PhD</last_name>
    <phone>+32 2 5553714</phone>
    <email>christophe.moreno@erasme.ulb.ac.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fran√ßoise Smits, Nurse</last_name>
    <phone>+32 2 5554478</phone>
    <email>francoise.smits@erasme.ulb.ac.be</email>
  </overall_contact_backup>
  <reference>
    <citation>Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009 Jun 25;360(26):2758-69. doi: 10.1056/NEJMra0805786. Review.</citation>
    <PMID>19553649</PMID>
  </reference>
  <reference>
    <citation>Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978 Aug;75(2):193-9.</citation>
    <PMID>352788</PMID>
  </reference>
  <reference>
    <citation>Mathurin P, Mendenhall CL, Carithers RL Jr, Ramond MJ, Maddrey WC, Garstide P, Rueff B, Naveau S, Chaput JC, Poynard T. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol. 2002 Apr;36(4):480-7.</citation>
    <PMID>11943418</PMID>
  </reference>
  <reference>
    <citation>Carithers RL Jr, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, Maddrey WC. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med. 1989 May 1;110(9):685-90.</citation>
    <PMID>2648927</PMID>
  </reference>
  <reference>
    <citation>European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol. 2012 Aug;57(2):399-420. doi: 10.1016/j.jhep.2012.04.004. Epub 2012 May 26.</citation>
    <PMID>22633836</PMID>
  </reference>
  <reference>
    <citation>O'Shea RS, Dasarathy S, McCullough AJ; Practice Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology. 2010 Jan;51(1):307-28. doi: 10.1002/hep.23258. Review.</citation>
    <PMID>20034030</PMID>
  </reference>
  <reference>
    <citation>Mathurin P, O'Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, Ramond MJ, Naveau S, Maddrey WC, Morgan TR. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2011 Feb;60(2):255-60. doi: 10.1136/gut.2010.224097. Epub 2010 Oct 12.</citation>
    <PMID>20940288</PMID>
  </reference>
  <reference>
    <citation>Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, Downs N, Gleeson D, MacGilchrist A, Grant A, Hood S, Masson S, McCune A, Mellor J, O'Grady J, Patch D, Ratcliffe I, Roderick P, Stanton L, Vergis N, Wright M, Ryder S, Forrest EH; STOPAH Trial. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015 Apr 23;372(17):1619-28. doi: 10.1056/NEJMoa1412278.</citation>
    <PMID>25901427</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>May 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2017</study_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>alcoholic hepatitis</keyword>
  <keyword>spontaneous improvement</keyword>
  <keyword>corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

